{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,19]],"date-time":"2025-12-19T10:08:27Z","timestamp":1766138907965,"version":"3.44.0"},"reference-count":51,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"12","license":[{"start":{"date-parts":[[2024,10,2]],"date-time":"2024-10-02T00:00:00Z","timestamp":1727827200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":["Kidney360"],"published-print":{"date-parts":[[2024,12]]},"abstract":"<jats:p>Systemic amyloidoses are a group of disorders that can be hereditary or acquired and have various renal manifestations and outcomes. Light chain amyloid has been considered the most common renal amyloid and, thus, has been the focus of substantial research and therapeutic interest but with improvement in diagnostic techniques. However, there has been growing interest in rarer forms of renal amyloid, including amyloid serum A protein, leukocyte chemotactic factor 2 amyloid, and transthyretin amyloid. In this review, we provide an update on diagnostics, renal outcomes, and therapeutic landscape in these specific types of amyloid.<\/jats:p>","DOI":"10.34067\/kid.0000000600","type":"journal-article","created":{"date-parts":[[2024,10,2]],"date-time":"2024-10-02T12:05:03Z","timestamp":1727870703000},"page":"1925-1937","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":4,"title":["Kidney Disease in Systemic Amyloidosis"],"prefix":"10.34067","volume":"5","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9347-6299","authenticated-orcid":false,"given":"Raad","family":"Chowdhury","sequence":"first","affiliation":[{"name":"Division of Kidney Medicine, Brigham and Women's Hospital, Boston, Massachusetts"},{"name":"Department of Medical Oncology, Dana Farber Cancer Institute, Boston, Massachusetts"},{"name":"Harvard Medical School, Boston, Massachusetts"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0125-1448","authenticated-orcid":false,"given":"Sujal","family":"Shah","sequence":"additional","affiliation":[{"name":"Division of Kidney Medicine, Brigham and Women's Hospital, Boston, Massachusetts"},{"name":"Harvard Medical School, Boston, Massachusetts"},{"name":"Department of Pathology, Brigham and Women's Hospital, Boston, Massachusetts"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5159-9680","authenticated-orcid":false,"given":"Sheron","family":"Latcha","sequence":"additional","affiliation":[{"name":"Memorial Sloan Kettering Cancer Center, New york, NY"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1464-083X","authenticated-orcid":false,"given":"Luisa","family":"Lobato","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Centro Hospitalar Universit\u00e1rio de Santo Ant\u00f3nio (CHUdSA), Porto, Portugal"},{"name":"UMIB - Unit for Multidisciplinary Research in Biomedicine, ICBAS - School of Medicine and Biomedical Sciences, University of Porto, Porto, Portugal"},{"name":"ITR - Laboratory for Integrative and Translational Research in Population Health, University of Porto, Porto, Portugal"}]}],"member":"276","published-online":{"date-parts":[[2024,10,2]]},"reference":[{"issue":"9","key":"B1-20250823","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.2215\/CJN.10491012","article-title":"Renal amyloidosis: origin and clinicopathologic correlations of 474 recent cases","volume":"8","author":"Said","year":"2013","journal-title":"Clin J Am Soc Nephrol."},{"issue":"4","key":"B2-20250823","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1080\/13506129.2022.2147636","article-title":"Amyloid nomenclature 2022: update, novel proteins, and recommendations by the International Society of amyloidosis (ISA) nomenclature Committee","volume":"29","author":"Buxbaum","year":"2022","journal-title":"Amyloid."},{"issue":"8","key":"B3-20250823","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1373\/clinchem.2009.126664","article-title":"Screening panels for detection of monoclonal gammopathies","volume":"55","author":"Katzmann","year":"2009","journal-title":"Clin Chem."},{"issue":"15","key":"B4-20250823","doi-asserted-by":"crossref","first-page":"2325","DOI":"10.1182\/blood-2014-04-570010","article-title":"A staging system for renal outcome and early markers of renal response to chemotherapy in AL amyloidosis","volume":"124","author":"Palladini","year":"2014","journal-title":"Blood."},{"issue":"9","key":"B5-20250823","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1093\/ndt\/gfy291","article-title":"AL amyloidosis: advances in diagnostics and treatment","volume":"34","author":"Rysava","year":"2019","journal-title":"Nephrol Dial Transplant."},{"issue":"4","key":"B6-20250823","doi-asserted-by":"crossref","first-page":"629","DOI":"10.3390\/ph16040629","article-title":"Clinical confirmation of pan-amyloid reactivity of radioiodinated peptide (124)I-p5+14 (AT-01) in patients with diverse types of systemic amyloidosis demonstrated by PET\/CT imaging","volume":"16","author":"Martin","year":"2023","journal-title":"Pharmaceuticals (Basel)."},{"issue":"6","key":"B7-20250823","doi-asserted-by":"crossref","first-page":"2015","DOI":"10.1002\/art.21902","article-title":"Diagnostic accuracy of subcutaneous abdominal fat tissue aspiration for detecting systemic amyloidosis and its utility in clinical practice","volume":"54","author":"van Gameren","year":"2006","journal-title":"Arthritis Rheum."},{"issue":"7","key":"B8-20250823","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1080\/07853890.2017.1304649","article-title":"Overuse of organ biopsies in immunoglobulin light chain amyloidosis (AL): the consequence of failure of early recognition","volume":"49","author":"Muchtar","year":"2017","journal-title":"Ann Med."},{"issue":"suppl 1","key":"B9-20250823","doi-asserted-by":"crossref","first-page":"80","DOI":"10.3109\/13506129.2011.574354029","article-title":"The role of minor salivary gland biopsy in the diagnosis of systemic amyloidosis: results of a prospective study in 62 patients","volume":"18","author":"Foli","year":"2011","journal-title":"Amyloid."},{"issue":"9","key":"B10-20250823","doi-asserted-by":"crossref","first-page":"e0185078","DOI":"10.1371\/journal.pone.0185078","article-title":"Utility of abdominal skin plus subcutaneous fat and rectal mucosal biopsy in the diagnosis of AL amyloidosis with renal involvement","volume":"12","author":"Li","year":"2017","journal-title":"PLoS One."},{"issue":"1","key":"B11-20250823","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1080\/13506129.2021.1994386","article-title":"Tissue biopsy for the diagnosis of amyloidosis: experience from some centres","volume":"29","author":"Benson","year":"2022","journal-title":"Amyloid."},{"issue":"14","key":"B12-20250823","doi-asserted-by":"crossref","first-page":"2239","DOI":"10.1182\/blood-2014-11-609883","article-title":"A practical approach to the diagnosis of systemic amyloidoses","volume":"125","author":"Fernandez de Larrea","year":"2015","journal-title":"Blood."},{"issue":"24","key":"B13-20250823","doi-asserted-by":"crossref","first-page":"4957","DOI":"10.1182\/blood-2009-07-230722","article-title":"Classification of amyloidosis by laser microdissection and mass spectrometry-based proteomic analysis in clinical biopsy specimens","volume":"114","author":"Vrana","year":"2009","journal-title":"Blood."},{"issue":"16","key":"B14-20250823","doi-asserted-by":"crossref","first-page":"3206","DOI":"10.1182\/blood-2012-03-413682","article-title":"How I treat amyloidosis: the importance of accurate diagnosis and amyloid typing","volume":"120","author":"Leung","year":"2012","journal-title":"Blood."},{"issue":"17","key":"B15-20250823","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1056\/NEJM199704243361702","article-title":"A trial of three regimens for primary amyloidosis: colchicine alone, melphalan and prednisone, and melphalan, prednisone, and colchicine","volume":"336","author":"Kyle","year":"1997","journal-title":"New Engl J Med."},{"issue":"11","key":"B16-20250823","doi-asserted-by":"crossref","first-page":"2245","DOI":"10.1001\/archinte.1992.00400230061010","article-title":"Dialysis support of patients with primary systemic amyloidosis. A study of 211 patients","volume":"152","author":"Gertz","year":"1992","journal-title":"Arch Intern Med."},{"issue":"9","key":"B17-20250823","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1200\/JCO.2011.38.5724","article-title":"Revised prognostic staging system for light chain amyloidosis incorporating cardiac biomarkers and serum free light chain measurements","volume":"30","author":"Kumar","year":"2012","journal-title":"J Clin Oncol."},{"issue":"1","key":"B18-20250823","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1056\/NEJMoa2028631","article-title":"Daratumumab-based treatment for immunoglobulin light-chain amyloidosis","volume":"385","author":"Kastritis","year":"2021","journal-title":"New Engl J Med."},{"issue":"25","key":"B19-20250823","doi-asserted-by":"crossref","first-page":"2632","DOI":"10.1182\/blood.2020009039","article-title":"Phase 1a\/b study of monoclonal antibody CAEL-101 (11-1F4) in patients with AL amyloidosis","volume":"138","author":"Edwards","year":"2021","journal-title":"Blood."},{"issue":"suppl 1","key":"B20-20250823","doi-asserted-by":"crossref","first-page":"3166","DOI":"10.1182\/blood-2019-124482","article-title":"Results of the phase 3 VITAL study of NEOD001 (birtamimab) plus standard of care in patients with light chain (AL) amyloidosis suggest survival benefit for Mayo stage IV patients","volume":"134","author":"Gertz","year":"2019","journal-title":"Blood."},{"issue":"3","key":"B21-20250823","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/j.kint.2022.10.028","article-title":"Renal AA amyloidosis: presentation, diagnosis, and current therapeutic options: a review","volume":"103","author":"Karam","year":"2023","journal-title":"Kidney Int."},{"issue":"23","key":"B22-20250823","doi-asserted-by":"crossref","first-page":"2361","DOI":"10.1056\/NEJMoa070265","article-title":"Natural history and outcome in systemic AA amyloidosis","volume":"356","author":"Lachmann","year":"2007","journal-title":"New Engl J Med."},{"issue":"1","key":"B23-20250823","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1002\/art.21518","article-title":"Acute-phase serum amyloid A stimulation of angiogenesis, leukocyte recruitment, and matrix degradation in rheumatoid arthritis through an NF-kappaB-dependent signal transduction pathway","volume":"54","author":"Mullan","year":"2006","journal-title":"Arthritis Rheum."},{"issue":"7","key":"B24-20250823","doi-asserted-by":"crossref","first-page":"4300","DOI":"10.1074\/jbc.274.7.4300","article-title":"Activation of Sp1 and its functional Co-operation with serum amyloid A-activating sequence binding factor in synoviocyte cells trigger synergistic action of interleukin-1 and interleukin-6 in serum amyloid A gene expression","volume":"274","author":"Ray","year":"1999","journal-title":"J Biol Chem."},{"issue":"16","key":"B25-20250823","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1056\/NEJM198604173141601","article-title":"Colchicine in the prevention and treatment of the amyloidosis of familial mediterranean fever","volume":"314","author":"Zemer","year":"1986","journal-title":"New Engl J Med."},{"issue":"23","key":"B26-20250823","doi-asserted-by":"crossref","first-page":"2349","DOI":"10.1056\/NEJMoa065644","article-title":"Eprodisate for the treatment of renal disease in AA amyloidosis","volume":"356","author":"Dember","year":"2007","journal-title":"New Engl J Med."},{"issue":"422","key":"B27-20250823","doi-asserted-by":"crossref","first-page":"eaan3128","DOI":"10.1126\/scitranslmed.aan3128","article-title":"Repeat doses of antibody to serum amyloid P component clear amyloid deposits in patients with systemic amyloidosis","volume":"10","author":"Richards","year":"2018","journal-title":"Sci Transl Med."},{"issue":"1","key":"B28-20250823","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1186\/s13023-022-02405-7","article-title":"An observational, non-interventional study for the follow-up of patients with amyloidosis who received miridesap followed by dezamizumab in a phase 1 study","volume":"17","author":"Richards","year":"2022","journal-title":"Orphanet J Rare Dis."},{"issue":"2","key":"B29-20250823","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1038\/ki.2008.152","article-title":"Leukocyte chemotactic factor 2: a novel renal amyloid protein","volume":"74","author":"Benson","year":"2008","journal-title":"Kidney Int."},{"issue":"2","key":"B30-20250823","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1038\/ki.2013.558","article-title":"Characterization and outcomes of renal leukocyte chemotactic factor 2-associated amyloidosis","volume":"86","author":"Said","year":"2014","journal-title":"Kidney Int."},{"issue":"3","key":"B31-20250823","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1093\/ndt\/gfm684","article-title":"Renal involvement in systemic amyloidosis: an Italian collaborative study on survival and renal outcome","volume":"23","author":"Bergesio","year":"2007","journal-title":"Nephrol Dial Transplant."},{"key":"B32-20250823","doi-asserted-by":"crossref","first-page":"107375","DOI":"10.1016\/j.carpath.2021.107375","article-title":"Clinically occult amyloidosis derived from leukocyte chemotactic factor 2 (ALECT 2) with cardiac involvement complicating renal transplantation: case report and literature review","volume":"55","author":"Eletta","year":"2021","journal-title":"Cardiovasc Pathol."},{"issue":"4","key":"B33-20250823","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1038\/modpathol.2016.29","article-title":"Leukocyte chemotactic factor 2 amyloidosis (ALECT2) is a common form of renal amyloidosis among Egyptians","volume":"29","author":"Larsen","year":"2016","journal-title":"Mod Pathol."},{"key":"B34-20250823","doi-asserted-by":"crossref","first-page":"900313","DOI":"10.3389\/fcvm.2022.900313","article-title":"Clinical profile and prognosis of hereditary transthyretin amyloid cardiomyopathy: a single-center study in South China","volume":"9","author":"Wang","year":"2022","journal-title":"Front Cardiovasc Med."},{"issue":"7","key":"B35-20250823","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1093\/eurheartj\/ehs238","article-title":"Getting to the heart of the matter: cardiac involvement in transthyretin-related amyloidosis","volume":"34","author":"Zeldenrust","year":"2013","journal-title":"Eur Heart J."},{"issue":"8","key":"B36-20250823","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.2215\/CJN.08720811","article-title":"Transthyretin amyloidosis and the kidney","volume":"7","author":"Lobato","year":"2012","journal-title":"Clin J Am Soc Nephrol."},{"issue":"9","key":"B37-20250823","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1093\/ckj\/sfac118","article-title":"Kidney involvement in hereditary transthyretin amyloidosis: a cohort study of 103 patients","volume":"15","author":"Solignac","year":"2022","journal-title":"Clin Kidney J."},{"issue":"12","key":"B38-20250823","doi-asserted-by":"crossref","first-page":"2080","DOI":"10.1002\/prot.26399","article-title":"Analysis of amyloidogenic transthyretin mutations using continuum solvent free energy calculations","volume":"90","author":"Hartmann","year":"2022","journal-title":"Proteins."},{"issue":"4","key":"B39-20250823","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1159\/000522226","article-title":"Genetic etiologies for chronic kidney disease revealed through next-generation renal gene panel","volume":"53","author":"Bleyer","year":"2022","journal-title":"Am J Nephrol."},{"issue":"3","key":"B40-20250823","doi-asserted-by":"crossref","first-page":"142","DOI":"10.3109\/13506129.2013.797890","article-title":"Amyloid fibrils containing fragmented ATTR may be the standard fibril composition in ATTR amyloidosis","volume":"20","author":"Ihse","year":"2013","journal-title":"Amyloid."},{"issue":"1","key":"B41-20250823","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1002\/ehf2.14188","article-title":"SGLT2 inhibitor therapy for transthyretin amyloid cardiomyopathy: early tolerance and clinical response to dapagliflozin","volume":"10","author":"Dobner","year":"2023","journal-title":"ESC Heart Fail."},{"issue":"2","key":"B42-20250823","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1007\/s10741-023-10380-9","article-title":"Molecular mechanisms and emerging therapies in wild-type transthyretin amyloid cardiomyopathy","volume":"29","author":"Wu","year":"2024","journal-title":"Heart Fail Rev."},{"issue":"suppl 1","key":"B43-20250823","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1080\/13506129.2016.1277697","article-title":"Transthyretin (ATTR) amyloidosis nephropathy: lessons from a TTR stabilizer molecule","volume":"24","author":"Rocha","year":"2017","journal-title":"Amyloid."},{"issue":"2","key":"B44-20250823","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1093\/ckj\/sfac156","article-title":"Kidney involvement in hereditary transthyretin amyloidosis: is there a role for cystatin C?","volume":"16","author":"D'Ambrosio","year":"2023","journal-title":"Clin Kidney J."},{"issue":"2","key":"B45-20250823","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1016\/j.jaccao.2024.02.007","article-title":"Effect of tafamidis on renal function in patients with transthyretin amyloid cardiomyopathy in ATTR-ACT","volume":"6","author":"Sperry","year":"2024","journal-title":"JACC Cardio Oncol."},{"issue":"2","key":"B46-20250823","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1056\/NEJMoa2305434","article-title":"Efficacy and safety of acoramidis in transthyretin amyloid cardiomyopathy","volume":"390","author":"Gillmore","year":"2024","journal-title":"New Engl J Med."},{"issue":"4","key":"B47-20250823","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1111\/jns.12519","article-title":"Liver-directed drugs for transthyretin-mediated amyloidosis","volume":"27","author":"Brannagan","year":"2022","journal-title":"J Peripher Nerv Syst."},{"issue":"5","key":"B48-20250823","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1053\/j.ajkd.2022.08.018","article-title":"Focal segmental glomerulosclerosis complicating therapy with inotersen, an antisense oligonucleotide inhibitor: a case report","volume":"81","author":"Law","year":"2023","journal-title":"Am J Kidney Dis."},{"issue":"4","key":"B49-20250823","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1007\/s40265-024-02008-5","article-title":"Eplontersen: first approval","volume":"84","author":"Nie","year":"2024","journal-title":"Drugs."},{"issue":"2","key":"B50-20250823","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1002\/ejhf.3138","article-title":"Impact of vutrisiran on exploratory cardiac parameters in hereditary transthyretin-mediated amyloidosis with polyneuropathy","volume":"26","author":"Garcia-Pavia","year":"2024","journal-title":"Eur J Heart Fail."},{"issue":"1","key":"B51-20250823","first-page":"e202304","article-title":"Lessons from the first-in-human in vivo CRISPR\/Cas9 editing of the TTR gene by NTLA-2001 trial in patients with transthyretin amyloidosis with cardiomyopathy","volume":"2023","author":"Kotit","year":"2023","journal-title":"Glob Cardiol Sci Pract."}],"container-title":["Kidney360"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.34067\/KID.0000000600","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,23]],"date-time":"2025-08-23T17:00:38Z","timestamp":1755968438000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.34067\/KID.0000000600"}},"subtitle":["A Review of Amyloid, Amyloid Serum A Protein, Leukocyte Chemotactic Factor 2, and Transthyretin Amyloid"],"short-title":[],"issued":{"date-parts":[[2024,10,2]]},"references-count":51,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.34067\/kid.0000000600","relation":{},"ISSN":["2641-7650"],"issn-type":[{"type":"electronic","value":"2641-7650"}],"subject":[],"published":{"date-parts":[[2024,10,2]]}}}